| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2500036 | Farmacia Hospitalaria | 2012 | 6 Pages |
Abstract
combined prescription has decreased since the first warning, above all in patients with a primary circulatory heart disease. Omeprazole is a potent CYP2C19 inhibitor, so it was used in lower rates than pantoprazole in association with clopidogrel. Medical departments related to cardiovascular disease followed the warning more than others.
Keywords
Related Topics
Health Sciences
Pharmacology, Toxicology and Pharmaceutical Science
Pharmaceutical Science
Authors
M. Sánchez Ruiz-Gordoa, J.M. TenÃas Burillo, R. Ruiz MartÃn de la Torre, J.C. Valenzuela Gámez,